InsidersTradesSigma
Total declarations
Company
▲ Purchases (21 ops.)
▼ Sales (0 ops.)
Browse the detailed record of transactions filed by ALSTODT LANCE, Chairman & CEO. Director active across 1 company, notably BioRestorative Therapies, Inc.. In total, 22 filings have been published. Breakdown: 21 buys · 0 sell. Total volume traded: €94k. History available since 16 November 2021. The latest transaction was filed on 30 June 2022 (Acquisition). Regulator: SEC (Form 4). The full history is openly available.
Declarations22 total
1,100 shares@ US$3.09810.066% mcap3.5% of flowCommon StockSEC:0001567619-22-013553:0
Ideal exit: 27 Mar 2023 (T+270)
600 shares@ US$3.730.043% mcap2.3% of flowCommon StockSEC:0001567619-22-013067:0
Ideal exit: 13 Mar 2023 (T+270)
700 shares@ US$3.68220.050% mcap2.6% of flowCommon StockSEC:0001567619-22-012910:0
Ideal exit: 12 Mar 2023 (T+270)
500 shares@ US$3.91190.038% mcap2.0% of flowCommon StockSEC:0001567619-22-012867:0
Ideal exit: 11 Mar 2023 (T+270)
100 shares@ US$3.980.0078% mcap0.4% of flowCommon StockSEC:0001567619-22-012812:0
Ideal exit: 10 Mar 2023 (T+270)
100 shares@ US$4.280.0082% mcap0.4% of flowCommon StockSEC:0001567619-22-012581:0
Ideal exit: 5 Mar 2023 (T+270)
200 shares@ US$4.600.018% mcap0.9% of flowCommon StockSEC:0001567619-22-012211:0
Ideal exit: 26 Feb 2023 (T+270)
2,700 shares@ US$3.51630.18% mcap9.4% of flowCommon StockSEC:0001567619-22-011807:0
Ideal exit: 20 Feb 2023 (T+270)
200 shares@ US$3.9350.015% mcap0.8% of flowCommon StockSEC:0001567619-22-009300:0
Ideal exit: 27 Jan 2023 (T+270)
12,438 sharesCommon StockSEC:0001567619-22-007347:0
1,470 shares@ US$3.400.090% mcap4.7% of flowCommon StockSEC:0001567619-22-001588:0
Ideal exit: 21 Oct 2022 (T+270)
1,470 shares@ US$3.4012.0% of flowCommon StockSEC:0001567619-22-001588
Ideal exit: 21 Oct 2022 (T+270)
2,000 shares@ US$3.850.14% mcap7.2% of flowCommon StockSEC:0001567619-22-000585:0
Ideal exit: 2 Oct 2022 (T+270)
2,000 shares@ US$3.8518.6% of flowCommon StockSEC:0001567619-22-000585
Ideal exit: 2 Oct 2022 (T+270)
799 shares@ US$5.5010.6% of flowCommon StockSEC:0001567619-21-021415
Ideal exit: 28 Aug 2022 (T+270)
799 shares@ US$5.500.079% mcap4.1% of flowCommon StockSEC:0001567619-21-021415:0
Ideal exit: 28 Aug 2022 (T+270)
2,500 shares@ US$6.000.27% mcap14.2% of flowCommon StockSEC:0001567619-21-021072:0
Ideal exit: 20 Aug 2022 (T+270)
2,500 shares@ US$6.0036.4% of flowCommon StockSEC:0001567619-21-021072
Ideal exit: 20 Aug 2022 (T+270)
396 shares@ US$6.316.1% of flowCommon StockSEC:0001567619-21-020992
Ideal exit: 19 Aug 2022 (T+270)
396 shares@ US$6.310.045% mcap2.4% of flowCommon StockSEC:0001567619-21-020992:0
Ideal exit: 19 Aug 2022 (T+270)
1,000 shares@ US$6.760.12% mcap6.3% of flowCommon StockSEC:0001567619-21-020595:0
Ideal exit: 13 Aug 2022 (T+270)
1,000 shares@ US$6.7616.2% of flowCommon StockSEC:0001567619-21-020595
Ideal exit: 13 Aug 2022 (T+270)
22 of 22 declarations
About ALSTODT LANCE
Lance Alstodt is an executive at BioRestorative Therapies, Inc.
